EnClear Therapies is a biotechnology company focused on improving and extending the lives of patients with central nervous system (CNS) diseases through precision dosing. The company operates in the neuro-oncology and neurodegenerative disease markets, leveraging its proprietary EnTrega CSF Platform for controlled, continuous, and personalized delivery of therapeutics. EnClear Therapies serves patients with conditions such as Leptomeningeal Carcinomatosis and aims to expand into neurodegenerative, lysosomal storage, and autoimmune diseases through strategic partnerships. The business model involves developing and commercializing a pipeline of patient-focused opportunities, generating revenue through the sale and licensing of its therapeutic solutions. The company brings together a multidisciplinary team with a proven track record in biomedical technology and market development.

Keywords: CNS diseases, precision dosing, neuro-oncology, neurodegenerative, EnTrega CSF Platform, personalized delivery, Leptomeningeal Carcinomatosis, lysosomal storage, autoimmune diseases, biomedical technology.